Edward A FitzGerald
Overview
Explore the profile of Edward A FitzGerald including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
877
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
FitzGerald E, Rachman M, Cederfelt D, Myers N, Kovryzchenko D, Zhang H, et al.
Bioorg Med Chem
. 2025 Mar;
121:118134.
PMID: 40024141
SMYD3 (SET- and MYND-domain containing protein 3) is an epigenetic enzyme with lysine methyl transferase activity and multiple protein binding partners. It is implicated in cancer development and active site...
2.
Grosjean H, Aimon A, Hassell-Hart S, Thompson W, Koekemoer L, Bennett J, et al.
Angew Chem Int Ed Engl
. 2025 Feb;
:e202424373.
PMID: 39931803
Fragment approaches are long-established in target-based ligand discovery yet their full transformative potential lies dormant, because progressing hits to potency remains underserved by methodological work. The only credible progression paradigm...
3.
FitzGerald E, Cederfelt D, Lund B, Myers N, Zhang H, Dobritzsch D, et al.
RSC Med Chem
. 2024 Jun;
15(6):1982-1990.
PMID: 38911161
A 1056-membered fragment library has been screened against SMYD3 using a novel multiplexed experimental design implemented in a grating coupled interferometry (GCI)-based biosensor. SMYD3 is a prospective target for anticancer...
4.
Pal S, Nare Z, Rao V, Smith B, Morrison I, FitzGerald E, et al.
ChemMedChem
. 2024 Feb;
19(6):e202300590.
PMID: 38372199
We report the development of BioPhysical and Active Learning Screening (BioPALS); a rapid and versatile hit identification protocol combining AI-powered virtual screening with a GCI-driven biophysical confirmation workflow. Its application...
5.
FitzGerald E, Vagrys D, Opassi G, Klein H, Hamilton D, Talibov V, et al.
SLAS Discov
. 2023 Sep;
29(1):40-51.
PMID: 37714432
Surface plasmon resonance (SPR) biosensor methods are ideally suited for fragment-based lead discovery. However, generally applicable experimental procedures and detailed protocols are lacking, especially for structurally or physico-chemically challenging targets...
6.
FitzGerald E, Butko M, Boronat P, Cederfelt D, Abramsson M, Ludviksdottir H, et al.
RSC Adv
. 2022 Apr;
11(13):7527-7537.
PMID: 35423271
Biophysical screening of compound libraries for the identification of ligands that interact with a protein is efficient, but does typically not reveal if (or how) ligands may interfere with its...
7.
Talibov V, Fabini E, FitzGerald E, Tedesco D, Cederfeldt D, Talu M, et al.
Chembiochem
. 2021 Jan;
22(9):1597-1608.
PMID: 33400854
SMYD3 is a multifunctional epigenetic enzyme with lysine methyltransferase activity and various interaction partners. It is implicated in the pathophysiology of cancers but with an unclear mechanism. To discover tool...
8.
Herland A, Maoz B, FitzGerald E, Grevesse T, Vidoudez C, Sheehy S, et al.
Adv Biosyst
. 2020 Aug;
4(9):e1900230.
PMID: 32744807
The functional state of the neurovascular unit (NVU), composed of the blood-brain barrier and the perivasculature that forms a dynamic interface between the blood and the central nervous system (CNS),...
9.
Novak R, Ingram M, Marquez S, Das D, Delahanty A, Herland A, et al.
Nat Biomed Eng
. 2020 Jan;
4(4):407-420.
PMID: 31988458
Organ chips can recapitulate organ-level (patho)physiology, yet pharmacokinetic and pharmacodynamic analyses require multi-organ systems linked by vascular perfusion. Here, we describe an 'interrogator' that employs liquid-handling robotics, custom software and...
10.
Park T, Mustafaoglu N, Herland A, Hasselkus R, Mannix R, FitzGerald E, et al.
Nat Commun
. 2019 Jun;
10(1):2621.
PMID: 31197168
The high selectivity of the human blood-brain barrier (BBB) restricts delivery of many pharmaceuticals and therapeutic antibodies to the central nervous system. Here, we describe an in vitro microfluidic organ-on-a-chip...